Orby.co Company Profile

Background

Mission and Vision

Orby.co is dedicated to restoring autonomy and enhancing the quality of life through non-invasive neurotechnology integrated with artificial intelligence. By improving sensory, motor, autonomic, and cognitive functions, the company aims to unlock the full potential of the nervous system. Their mission is to translate cutting-edge science into real-world impact, expanding human experience and transforming lives at scale.

Primary Area of Focus and Industry Significance

Operating within the neurotechnology sector, Orby.co focuses on developing non-invasive neuromodulation systems designed for clinical environments. Their flagship product, OrTECH, combines hardware, software, and AI to deliver bio-inspired signals that activate the nervous system, promoting movement restoration and pain relief. This approach addresses the critical need for effective, accessible neurorehabilitation solutions without the risks and costs associated with invasive implants.

Key Strategic Focus

Core Objectives

Orby.co aims to automate and integrate medical processes to deliver an excellent medical experience to everyone. Their strategic focus includes developing scalable, non-invasive neurotechnology solutions that can be seamlessly integrated into clinical settings, thereby improving patient outcomes and expanding the reach of advanced rehabilitation therapies.

Specific Areas of Specialization

• Non-Invasive Neuromodulation: Developing devices that provide therapeutic effects without the need for surgical interventions.

• Artificial Intelligence Integration: Utilizing AI to analyze physiological signals and adapt therapies in real-time, ensuring personalized treatment plans.

• Clinical Rehabilitation: Focusing on motor rehabilitation and pain management to address common medical needs.

Key Technologies Utilized

• OrTECH Device: A portable neuromodulation device with 2 to 4 stimulation channels, embedded with proprietary AI algorithms and advanced sensors.

• OrTECH OS: An operating system that powers the OrTECH device, enabling digital medical records, real-time therapy monitoring, and detailed biofeedback reports.

Primary Markets Targeted

Orby.co primarily targets healthcare providers, including clinics, hospitals, and health insurers, focusing on patients with neuromotor dysfunctions, chronic pain, or those in intensive care. Their solutions are designed to be scalable and adaptable, catering to a wide range of clinical environments.

Financials and Funding

Funding History

Orby.co has secured funding through various channels, including participation in acceleration programs and competitions. Notably, they received a prize of R$ 150,000 from the BNDES Garagem program, which is intended to support the scaling of their operations and consolidation of their technology in the market.

Total Funds Raised

Specific details regarding the total funds raised by Orby.co are not publicly disclosed.

Notable Investors

While specific investors are not publicly listed, Orby.co has been recognized and supported by various innovation and acceleration programs, indicating strong investor confidence in their mission and technology.

Intended Utilization of Capital

The capital raised is primarily intended to scale Orby.co's operations, enhance research and development efforts, and expand their market presence, particularly in the clinical rehabilitation sector.

Pipeline Development

Key Pipeline Candidates

Orby.co's primary focus is on the development and deployment of their flagship product, the OrTECH device, which is designed to provide non-invasive neuromodulation therapies for motor rehabilitation and pain management.

Stages of Clinical Trials or Product Development

As of the latest available information, Orby.co is in the advanced stages of product development, with their OrTECH device being utilized in clinical settings. Specific details regarding clinical trials are not publicly disclosed.

Target Conditions

The OrTECH device targets conditions such as neuromotor dysfunctions, chronic pain, and rehabilitation needs in intensive care patients.

Relevant Timelines for Anticipated Milestones

While specific timelines for future milestones are not publicly disclosed, Orby.co continues to focus on scaling their technology and expanding its application in clinical environments.

Technological Platform and Innovation

Proprietary Technologies

• OrTECH Device: A non-invasive neuromodulation system integrating multiple stimulation channels, AI algorithms, and advanced sensors.

• OrTECH OS: An operating system that supports the OrTECH device, facilitating digital medical records, real-time therapy monitoring, and biofeedback reporting.

Significant Scientific Methods

• AI-Driven Therapy Adaptation: Utilizing artificial intelligence to continuously adapt therapy parameters based on patient response and sensor data, ensuring personalized treatment plans.

• Non-Invasive Neuromodulation: Applying bio-inspired signals that mimic neural activity to enable motor control and pain relief without surgical interventions.

Leadership Team

• Duda Franklin – CEO

Biomedical Engineer and neuroscientist with a master’s degree in Neuroengineering and in Science, Technology, and Innovation. Recognized among Forbes Under 30 and MIT Innovators Under 35.

• Kalynda Gomes – Brand Strategist

Holds a Bachelor’s degree in Visual Arts and a Technical Diploma. Experienced in design, entrepreneurship, and innovation, internationally recognized for work shaping the future of health technology.

• Dario Pimentel – US Market Expansion Lead

Business development professional with international experience in sales and market expansion, having led growth strategies at TRACTIAN and SHI International. Civil Engineer with a strong background in AI-driven industry solutions and US market entry.

• Guilherme Chapiewski – Senior Director of Engineering at Google Search

Leads large-scale AI and infrastructure initiatives powering information access for billions worldwide. Former VP of Engineering at PayPal and advisor to high-growth companies through CapitalG.

• Andrea Rolim – Board Advisor

Experienced executive and board member at Dexco, Lojas Renner, and Grupo Fleury. Former President of Kimberly-Clark Brazil, leading large-scale operations and strategy in the consumer goods sector.

• Gustavo Fernandes – Board Advisor

Vice President of Oncology at Rede Américas (a joint initiative of Dasa and Amil) and General Director of Oncology at Dasa. Over two decades of experience in oncology; former Director at Hospital Sírio-Libanês in Brasília.

• Michael Lehmann – Board Advisor

Senior executive with over three decades of financial leadership across global industries. Began career at Knorr-Bremse in 1986, later CFO at MWM Motores Diesel Argentina, Autotex, and Volkswagen at Brasil.

• Paulo Carvão – Board Advisor

Senior Fellow at Harvard University, former CRO at IBM, and Electrical and Electronics Engineer from the Military Institute of Engineering.

• Paula Jereissati – Board Advisor

Innovative healthcare executive and board advisor; currently Head of Business Enablement, Systems & Transformation at LivaNova. Previously led Digital Health Strategy at Alcon.

• Vânia Bezerra – Board Advisor

Executive with over 20 years of experience in healthcare, currently Director of Social Commitment and member of the Executive Committee at Hospital Sírio-Libanês.

Competitor Profile

Market Insights and Dynamics

The neurotechnology market is experiencing rapid growth, driven by advancements in non-invasive neuromodulation technologies and increasing demand for effective rehabilitation solutions.

Competitor Analysis

Orby.co operates in a competitive landscape that includes:

• Ubica Robotics: Developer of autonomous robots for creating digital twins of physical retail environments.

• Corvus Robotics: Specialist in autonomous technology for inventory management within logistics and supply chain sectors.

• Verity: Provider of autonomous indoor drone systems for inventory management.

Strategic Collaborations and Partnerships

Orby.co has engaged in strategic collaborations aimed at enhancing innovation and expanding market reach, further strengthening its position within the neurotechnology and medical device sectors.